Actively Recruiting
A Multicenter Prospective Study of Risk Factors in Progressive Pulmonary Fibrosis
Led by Qianfoshan Hospital · Updated on 2023-11-18
610
Participants Needed
1
Research Sites
104 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This research aims to understand the risk factors, prevalence, and mortality associated with progressive pulmonary fibrosis (PPF) in patients who have interstitial lung disease (ILD) with pulmonary fibrosis visible on scans, excluding those with idiopathic pulmonary fibrosis (IPF). It focuses on identifying connections between patient characteristics and progression of the disease over time. Participants will have initial assessments including collection of personal and medical histories, blood samples, detailed lung imaging (high resolution computed tomography), lung function tests, and a 6-minute walk test. These evaluations will be repeated at 6 and 12 months, with additional blood samples and tests to monitor disease progression. Throughout the study, researchers will track lung function, exercise capacity, blood markers, and imaging results to measure disease progression and outcomes. The main goal is to link factors like age, gender, body mass index, and lung physiology scores to PPF progression over one year. The study extends up to 36 months to observe disease prevalence and long-term outcomes.
CONDITIONS
Brief Title
A Multicenter Prospective Study of Risk Factors in Progressive Pulmonary Fibrosis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- 18 to 80 years old
- Able and willing to sign informed consent
- Diagnosed with interstitial lung disease showing pulmonary fibrosis on imaging
You will not qualify if you...
- Diagnosed with idiopathic pulmonary fibrosis (IPF)
- Pregnant or breastfeeding
- Mental illness or cognitive impairment
- Currently participating in other clinical studies
- Unable to provide informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 36 months
Participants with interstitial lung disease and pulmonary fibrosis are observed to collect data on risk factors and disease progression.
Regular visits for assessments over 36 months
Trial Site Locations
Total: 1 location
1
The First Affiliated Hospital of Shandong First Medical University
Jinan, Shandong, China, 250000
Actively Recruiting
Research Team
Z
zhi guo, Doctor
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here